Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasmActive, not recruitingPhase 22026-08-24NCT03410875

3 results · Page 1 of 1

Swipe the table sideways for more columns.

9 results · Page 1 of 1

Swipe the table sideways for more columns.